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Introduction
The lymphatic vascular system serves key physiological func­
tions: it maintains fluid homeostasis by absorbing water and 
macromolecules from the interstitium, enables uptake of dietary 
lipids and vitamins in the intestine, and serves as a trafficking 
route for immune cells. The lymphatic vasculature consists of a 
highly branched network of capillaries and ducts that is present 
in most organs with the exception of the central nervous system 
and avascular tissues, such as cartilage. Unlike the blood vas­
culature, the lymphatic vasculature is blind ending (Fig. 1 A): 
its small capillaries funnel first into precollecting and larger col­
lecting vessels and then into the thoracic duct or the right lym­
phatic trunk, which drains lymph into the subclavian veins.
Malfunctioning of the lymphatic vasculature results in 
lymphedema formation and compromises immune function. 
In the past decade, tremendous progress has been achieved in 
understanding the mechanisms regulating the morphogenesis 
of lymphatic vasculature, mainly accomplished by genetically 
modified mouse models and discovery of mutations respon­
sible for human lymphedema syndromes. In addition, models, 
such as zebrafish and frog tadpoles, are emerging as powerful 
tools for studying lymphatic vascular development. In this re­
view, we will summarize the main mechanisms underlying the 
development of lymphatic vasculature and present an overview 
of several human diseases that are associated with lymphatic 
vessel abnormalities.
Mechanisms of lymph transport
The structure of the different lymphatic vascular compartments, 
such as capillaries, precollecting, and collecting lymphatic ves­
sels, reflects its dual role in fluid absorption and lymph trans­
port. We will briefly present the main aspects of lymph transport, 
which have been documented in more detail in recent reviews 
(Dejana et al., 2009; Zawieja, 2009).
Fluid and cell uptake by lymphatic capillaries. 
Lymphatic capillary endothelium has a unique junctional orga­
nization (Baluk et al., 2007; Dejana et al., 2009). Oak leaf–shaped 
endothelial cells are connected by discontinuous buttonlike 
junctions. Free overlapping cell edges anchored on each side by 
these junctions form “flap valves” (Fig. 1, B and C) through 
which fluid flows unidirectionally along pressure gradients from 
the interstitium into the capillary lumen. Actively sprouting 
lymphatic capillaries have continuous cell–cell junctions, sug­
gesting buttonlike junctions as characteristics of quiescent and 
functional lymphatic capillary endothelium (Baluk et al., 2007). 
Lymphatic capillaries lack mural cells and connect to the ECM 
via anchoring filaments (Leak and Burke, 1968), which prevent 
the collapse of capillaries upon the increase of interstitial pres­
sure (Fig. 1 B).
The lymphatic vasculature constitutes a highly specialized 
part of the vascular system that is essential for the mainte­
nance of interstitial fluid balance, uptake of dietary fat, 
and immune response. Recently, there has been an in­
creased awareness of the importance of lymphatic vessels 
in many common pathological conditions, such as tumor 
cell dissemination and chronic inflammation. Studies of 
embryonic development and genetically engineered animal 
models coupled with the discovery of mutations under­
lying human lymphedema syndromes have contributed to 
our understanding of mechanisms regulating normal and 
pathological lymphatic morphogenesis. It is now crucial to 
use this knowledge for the development of novel therapies 
for human diseases.
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Transport of lymph by collecting vessels. Lymph 
from lymphatic capillaries is first drained into the precollecting lym­
phatic vessels that have both lymphatic capillary (oak leaf–shaped 
lymphatic endothelial cells [LECs]) and collecting lymphatic vessel 
characteristics (valves). Collecting lymphatic vessels consist of a 
series of functional units, called lymphangions, separated by intra­
luminal valves, which ensure unidirectional lymph flow (Fig. 1 D). 
Collecting vessels are covered with a continuous basement mem­
brane and smooth muscle cells (SMCs). Endothelial cells in collect­
ing vessels are elongated and connected by continuous zipperlike 
junctions (Fig. 1 C). Continuous junctions and basement membrane 
prevent leakage of lymph during its transport.
Shear stress generated by transcapillary fluid flow regu­
lates the expression of junctional proteins, up­regulates leuko­
cyte adhesion molecules ICAM­1 and E­selectin, and promotes 
secretion of chemokine CCL21, mediating dendritic cell migra­
tion (Miteva et al., 2010). Thus, mechanical stimulation may 
be important for immune surveillance function of lymphatic 
vasculature. Dendritic cells first squeeze through pores that 
punctuate the sparse basement membrane of lymphatic capillar­
ies and, subsequently, reach the lumen through interendothelial 
flap valves (Fig. 1 B; Pflicke and Sixt, 2009). They are then 
transported toward the draining lymph nodes where they induce 
immune responses.
Figure 1. Organization of lymphatic vasculature. (A) The lymphatic vasculature resorbs fluid, macromolecules, and cells from the interstitium. (B) Mecha-
nism of lymph formation in capillaries. Interstitial components penetrate lymphatic capillaries via openings between LECs. The specialized structure of such 
openings prevents the return of lymph back to the interstitium. Anchoring filaments attach LECs to the ECM and prevent vessel collapse under conditions of 
increased interstitial pressure (black arrow). (C) Junctional organization of LECs in lymphatic capillaries and collecting vessels. Both “buttons” and “zippers” 
share a repertoire of adherens and tight junction–associated proteins (e.g., VE-cadherin, zonula occludens-1, occludin, and claudin-5). The main difference 
between them resides in their organization (Baluk et al., 2007). (D) Mechanism of lymph propulsion in collecting vessels. Coordinated opening and closure 
of lymphatic valves is important for efficient lymph transport. SMCs covering each lymphangion possess intrinsic contractile activity. EC, endothelial cell.
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lymph hearts located at the junctions of the lymphatic and venous 
systems control lymph flow (Kampmeier, 1969).
Lymphatic vascular morphogenesis
Lymphatic vascular development requires transdifferentiation 
of venous endothelial cells toward the lymphatic endothelial 
phenotype, separation of blood and lymphatic vasculature, sprout­
ing of lymphatic vessels, and lymphatic vascular maturation 
(Fig. 2 A). Over 20 genes orchestrate these processes in mice 
(Table I), and recently, lymphangiogenesis has also been exam­
ined in lower vertebrates, such as fish and frogs.
Establishment of LEC identity and lymphatic 
sprouting. Lymphatic vessels stem from preexisting blood 
vessels. Elegant lineage tracing by Srinivasan et al. (2007) dem­
onstrated the venous origin of the mammalian lymphatic vascu­
lature as previously proposed (Sabin, 1902; Kaipainen et al., 
1995). The venous origin of LECs has been confirmed in 
Xenopus laevis and zebrafish as shown by real­time imaging 
in the latter and, therefore, appears to be evolutionary conserved 
(Ny et al., 2005; Yaniv et al., 2006; Hogan et al., 2009a).
Lymphatic valves contain two semilunar leaflets, which 
are covered on both sides by a specialized endothelium an­
chored to the ECM core (Lauweryns and Boussauw, 1973). 
High lymph pressure upstream of a valve opens the valve and 
enables lymph flow, whereas reverse flow pushes the leaflets 
against each other and closes the valve (Fig. 1 D). Therefore, 
opening and closing of the valve depend on periodic changes in 
fluid pressure within collecting vessels. The number of valves 
per vessel segment varies depending on tissue type, being gen­
erally highest in organs with high hydrostatic pressure, e.g., legs 
in humans (Földi et al., 2006).
Cyclical compression and expansion of lymphatic ves­
sels by surrounding tissues and intrinsic pump forces gener­
ated by the spontaneous phasic contraction of SMCs regulate 
lymph propulsion (Zawieja, 2009). The origin of lymphatic 
SMCs is unknown, but they contain both smooth and striated 
muscle contractile proteins and, thus, differ from arteriole 
SMCs (Muthuchamy et al., 2003). Nitric oxide, hormones, and 
prostanoids control SMC contractions (Zawieja, 2009). In am­
phibians and reptiles, specialized pulsatile muscular organs or 
Figure 2. Main steps of mammalian lymphatic vascular development. (A) LECs are specified in embryonic veins, from where they sprout toward Vegf-c– 
producing mesodermal cells and aggregate to form lymph sacs. Further sprouting produces the lymphatic primary plexus composed of capillary-like vessels. 
Myeloid cells produce cytokines and regulate lymphatic vascular morphogenesis. Primary plexus is further remodeled to form collecting, precollect-
ing, and capillary compartments. Precollecting and collecting lymphatic vessels have intraluminal valves and basement membrane coverage. Collecting 
lymphatic vessels are surrounded by SMCs (red). (box) Genes important for collecting lymphatic vessel development. (B) LYVE-1 is the earliest known LEC 
marker. The transcription factor Prox1 is essential for the establishment of LEC identity, and its expression is controlled by Sox18. (C) Signaling via Vegf-c 
and Vegfr-3 regulates LEC sprouting and proliferation. The role of Vegfr-2–Vegfr-3 heterodimers and participation of Nrp2 in the Vegfr-2–Vegfr-3 complex 
are not fully understood. (D) Separation of lymphatic and blood vasculature requires platelet aggregation (also see Table I). Interaction of podoplanin on 
LECs and CLEC-2 on platelets triggers the Syk-, Slp76-, and PLC-2–dependent signaling cascade leading to platelet aggregation. O-glycosylation by 
T-synthase is important for podoplanin function.
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Table I. Knockout or mutant mouse models and their phenotypes according to stages of lymphatic vascular morphogenesis
Gene symbol Function Lymphatic vascular phenotype Expression pattern
LEC differentiation
Prox1 Transcription factor No LECs (/), chylous ascites (+/);  
loss of LEC identity, chylous ascites, obesity  
(Prox1f/f; Tie2-Cre; Wigle et al., 1999;  
Harvey et al., 2005; Johnson et al., 2008)
LECs, hepatocytes, lens fiber 
cells, pancreatic, lung,  
and intestinal endocrine 
cells, skeletal muscle,  
cardiomyocytes
Sox18 Transcription factor No LECs(/, on C57BL/6J background);  
abnormal patterning (+/); edema and chylous  
ascites (heterozygous ragged mutants;  
Pennisi et al., 2000; François et al., 2008)
Endothelial cells
Coup-TFII (NR2F2) Transcription factor No LECs (/, deletion at or before E9.5);  
edema, loss of LEC identity, and sprouting  
(/, deletion at later stages; Lin et al., 2010; 
Srinivasan et al., 2010)
Endothelial cells and SMCs
Lymphangiogenesis
Vegf-c–Vegfr-3 pathway
Vegfr3 Receptor tyrosine kinase Hypoplasia, chylous ascites (+/Chy, ENU-induced  
mutation, loss of tyrosine kinase activity;  
Karkkainen et al., 2001); lymph sacs formed  
and defective sprouting (homozygous deletion of  
ligand-binding domain; Zhang et al., 2010)
LECs, fenestrated blood  
vascular endothelial cells, 
blood vascular endothelial 
cells in tumors and during 
early embryogenesis
Vegfc Growth factor,  
ligand for Vegfr-3
No sprouting of LECs from veins (/);  
hypoplasia, chylous ascites (+/; Karkkainen  
et al., 2003)
Macrophages, SMCs,  
and subpopulation of 
mesenchymal cells during 
development
Nrp2 Coreceptor of Vegfr-3  
and semaphorins
Transient capillary hypoplasia, defective sprouting  
(/; Yuan et al., 2002; Xu et al., 2010)
Venous and lymphatic  
endothelial cells
Rac1 Rho GTPase Abnormal migration of LECs from veins (Rac1f/f;  
Tie1-Cre; D’Amico et al., 2009)
Broad
Clp24 Transmembrane protein Lymphangiectasia, ectopic mural cells  
(Clp24/; Clp24/; Vegfr3lacz/+ and Clp24/; 
Vegfr2lacz/+; Saharinen et al., 2010)
Endothelial cells
Tbx1 Transcription factor Hypoplasia and chylous ascites (Tbx1f/f;  
Tie2-Cre; Chen et al., 2010)
Vascular, including LECs
Ptpn14 (gene trap) Protein tyrosine phosphatase Hyperplasia of dermal lymphatic vessels in  
14% of mutants, paw or periorbital edema  
(Au et al., 2010)
Broad, including LECs
Adrenomedullin signaling
Adm  
(adrenomedullin)
Peptide vasodilator,  
ligand for Calcrl
Hypoplasia of jugular lymph sacs, decreased LEC  
proliferation, edema (/, CalcrlLoxP/–;Tie2-Cre;  
Fritz-Six et al., 2008)
Adrenal medulla, vascular 
SMCs and endothelial cells,  
cardiomyocytes
Ramp2 Coreceptor of Calcrl Hypoplasia of jugular lymph sacs, decreased LEC  
proliferation, edema (/, CalcrlLoxP/–;Tie2-Cre;  
Fritz-Six et al., 2008)
Broad, including LECs
Calcrl (calcitonin recep-
tor-like)
G protein–coupled receptor  
of adrenomedullin
Hypoplasia of jugular lymph sacs, decreased LEC  
proliferation, edema (/, CalcrlLoxP/–;Tie2-Cre;  
Fritz-Six et al., 2008)
Broad, including LECs
Other
Vezf Transcription factor Transient jugular lymphatic hypervascularization  
(+/; Kuhnert et al., 2005)
Broad
Tie1 Receptor tyrosine kinase Abnormal lymphatic patterning, dilated and  
disorganized lymphatic vessels (hypomorphic mice  
on outbred background; D’Amico et al., 2010)
Endothelial and hematopoietic  
cells
Separation of blood and lymphatic vessels
Platelet development
Meis1 Transcription factor Blood-filled lymphatic vessels (/; Carramolino  
et al., 2010)
Broad, including developing  
hematopoietic cells
Platelet aggregation
Slp76 Adaptor protein Blood-filled lymphatic vessels, chylous ascites  
(/; Abtahian et al., 2003)
Hematopoietic cells
ENU, N-ethyl-N-nitrosourea; PAC, P1-derived artificial chromosome.
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Gene symbol Function Lymphatic vascular phenotype Expression pattern
Plcg2 Phospholipase C, hydrolysis of 
phospholipids
Blood-filled lymphatic vessels, chylous ascites  
(/; Ichise et al., 2009)
Broad
Pdpn (podoplanin) Transmembrane glycoprotein Lymphangiectasia, abnormal lymph transport,  
lymphedema, blood-filled lymphatic vessels  
(/; Schacht et al., 2003; Bertozzi et al., 2010;  
Uhrin et al., 2010)
LECs, keratinocytes, alveolar 
type II cells, podocytes
C1galt1 (encodes T-syn-
thetase)
Glycosyltransferase, biosynthesis 
of core-1–derived O-glycans
Blood-filled lymphatic vessels, decreased levels of  
podoplanin (/; Fu et al., 2008)
Endothelial and hematopoietic 
cells
Clec-2 C-type lectin receptor Blood-filled lymphatic vessels (/; Bertozzi et al.,  
2010; Suzuki-Inoue et al., 2010)
Platelets, peripheral blood  
neutrophils
Syk Nonreceptor tyrosine kinase Blood-filled lymphatic vessels, chylous ascites,  
accumulation of myeloid cells in the dermis  
(/, Sykf/f;vav-cre; Abtahian et al., 2003;  
Bertozzi et al., 2010; Böhmer et al., 2010)
Other
Spred1/Spred2 Cytoplasmic adaptor proteins Blood-filled lymphatic vessels  
(Spred1/; Spred2/; Taniguchi et al., 2007)
Broad, including LECs
Remodeling, maturation, and valve morphogenesis
Tie/PI3-kinase signaling
Akt1 Ser/Thr kinase Capillary hypoplasia, valve agenesis, dilation,  
and decreased SMC coverage of small collecting  
lymphatic vessels (/; Zhou et al., 2010)
Broad
Angpt2 Growth factor, ligand of Tie  
receptor tyrosine kinases
Hypoplasia, chylous ascites, defective remodeling,  
and valve agenesis (/; Gale et al., 2002;  
Dellinger et al., 2008)
(Lymph) angiogenenic  
endothelial cells,  
hematopoietic cells 
Pi3kca (mutation blocking 
interaction with Ras)
Catalytic p110 isoform of  
PI3-kinase
Chylous ascites, hypoplasia, impaired sprouting,  
and branching of lymphatic capillaries  
(/; Gupta et al., 2007)
Broad
Pik3r1 Regulatory subunits of class IA 
PI3-kinases
Chylous ascites, intestinal lymphangiectasia,  
impaired sprouting, lymphatic, valve agenesis  
(/; Mouta-Bellum et al., 2009)
Broad
ECM assembly and interactions
Itga9 Adhesion Chylothorax, lymphatic valve agenesis  
(/; Itga9f/f ;Tie2-Cre and Itga9f/f; Cdh5 (PAC)-
CreERT2; Bazigou et al., 2009)
BECs and LECs (highest in 
valves), vascular SMCs
Fn1 (removal of EDA  
domain)
ECM component, ligand of Itg-9 Failure of lymphatic valve leaflet elongation  
(/; Bazigou et al., 2009)
Broad, including lymphatic 
valves
Emilin1 Elastic microfibril-associated 
protein
Hyperplasia and abnormal patterning of lymphatic  
vessels, reduction of anchoring filaments;  
impaired lymph drainage, increased lymph  
leakage (/; Danussi et al., 2008)
Broad, including LECs
Other
Aspp1 Cytoplasmic adaptor protein Impaired assembly of lymphatic vessels and  
collecting lymphatic vessel patterning, accumulation  
of « lymphatic islands » (/; Hirashima et al., 2008)
Endothelial cells
Efnb2 (mutation of PDZ 
binding site)
Ligand of EphB receptor tyrosine 
kinases
Impaired sprouting of capillaries, agenesis of  
lymphatic valves, ectopic mural cells, chylothorax,  
retrograde lymph flow (/; Mäkinen et al., 2005)
Arterial endothelial cells  
and SMCs, LECs (highest  
in the valves)
Foxc2 Transcription factor Impaired patterning of capillaries, no collecting  
lymphatic vessels, agenesis of lymphatic valves,  
ectopic mural cells, retrograde lymph flow  
(/; Dagenais et al., 2004; Petrova et al., 2004; 
Norrmén et al., 2009)
Arterial endothelial cells  
and SMCs, LECs (highest  
in the valves)
Elk3 (Net) Transcription factor Lymphangiectasia, chylothorax  
(/; Ayadi et al., 2001)
Endothelial cells
PU.1  
Csfr1
Transcription factor  
receptor for M-CSF1
Hyperplasia and abnormal patterning of dermal  
lymphatic vessels (/; Gordon et al., 2010)
Hematopoietic cells (stage 
dependent)
ENU, N-ethyl-N-nitrosourea; PAC, P1-derived artificial chromosome.
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also regulates LEC budding from veins (D’Amico et al., 2009). 
Interestingly, postnatal development of lymphatic vessels in or­
gans other than skin is Vegf­c/Vegfr­3 independent, and internal 
lymphatic capillaries regrow in mice with mutated Vegfr3 or upon 
Vegf­c depletion (Karkkainen et al., 2001; Mäkinen et al., 2001; 
Kärpänen et al., 2006b).
In zebrafish, the secreted protein Ccbe1 controls lymphatic 
sprouting from veins, and its function is conserved, as CCBE1 mu­
tations cause human syndrome presenting with lymphatic dysplasia 
(Alders et al., 2009; Hogan et al., 2009a; see Heredity lymphedema 
syndromes). The venous origin of LECs and conserved function of 
VEGF­C, VEGFR­3, and CCBE1 (Karkkainen et al., 2000, 2003; 
Ny et al., 2005; Küchler et al., 2006; Yaniv et al., 2006; Alders 
et al., 2009; Hogan et al., 2009a,b) clearly underpin the common 
origin of the vertebrate lymphatic vasculature. Nevertheless, within 
this common scheme, there seem to be differences between mam­
malian and zebrafish LEC behavior: in mice, lymphatic sprouting 
occurs after veins have formed, whereas zebrafish venous sprouts 
and lymphatic precursors emerge from the cardinal vein simul­
taneously (Bussmann et al., 2010). Half of those venous sprouts 
connect with intersegmental vessels to form veins, whereas other 
sprouts disconnect from the vein and migrate toward the horizon­
tal myoseptum region, constituting a pool of future LECs. These 
cells, called parachordal lymphangioblasts, migrate along arteries 
either dorsally to form intersegmental lymphatic vessels or ven­
trally to form the thoracic duct (Bussmann et al., 2010; Geudens 
et al., 2010). At 5 d after fertilization, a functional lymphatic sys­
tem has been established in the zebrafish trunk capable of taking 
up substances from the interstitium and of transporting lymph into 
the venous system (Küchler et al., 2006; Yaniv et al., 2006). Future 
studies will have to show whether the requirement for arteries in 
guiding LEC migration is a zebrafish­specific feature or whether 
this represents a general scheme among vertebrates: the anatomical 
proximity of mammalian arteries and lymphatic vessels has often 
been noted but commonly attributed to high arterial pressure and 
a need of absorbing extravasated water and proteins near arteries. 
Using zebrafish, a role for Notch/Dll4 signaling has been demon­
strated in guiding LECs along arteries (Geudens et al., 2010), and 
there might be earlier roles for Notch at the level of venous sprout­
ing (Liao et al., 2010). Interestingly, loss of the arterial regulator 
synectin also compromises the development of zebrafish lymphat­
ics (Hermans et al., 2010).
Hematopoietic cells and lymphatic vascular 
development. In mammals, lymphatic and blood vascula­
tures are connected only in a few defined locations where lymph 
is returned back to blood circulation. Platelets are important for 
keeping both vascular systems apart (Table I): platelet deple­
tion or defective platelet aggregation leads to abnormal lympho­
venous connections and blood­filled lymphatic vessels (Ichise 
et al., 2009; Bertozzi et al., 2010; Carramolino et al., 2010; Suzuki­
Inoue et al., 2010; Uhrin et al., 2010). According to the current 
model, platelets aggregate at sites of communication between 
the cardinal vein and lymph sacs and “seal off” lymphatic vessels 
from the vein (Fig. 2, A and D). Platelet aggregation is initiated by 
binding of the O­glycosylated mucoprotein podoplanin expressed 
on LECs to the Clec­2 receptor on platelets (Bertozzi et al., 2010; 
Uhrin et al., 2010). Clec­2 further induces intracellular signaling 
In mice, LECs are first specified in the anterior cardinal vein 
around embryonic day 9.5 (E9.5) when a subset of venous endo­
thelial cells expresses the transcription factor Prox1 and the lym­
phatic vessel hyaluronan receptor­1 (LYVE­1) in a polar manner 
(Fig. 2 B). Prox1/ mice do not develop any lymphatic structures 
because of failed budding and sprouting of LECs (Wigle and 
Oliver, 1999). The transcription factor Sox18 induces Prox1 ex­
pression, and Sox18/ mice develop edema caused by blockage 
of LEC development in the vein in certain genetic backgrounds 
(François et al., 2008). In vitro studies demonstrate SOX18 bind­
ing to the Prox1 promoter and show that PROX1 can confer lym­
phatic identity to blood endothelial cells (BECs; Hong et al., 2002; 
Petrova et al., 2002; François et al., 2008). Thus, Sox18 and Prox1 
constitute an essential signaling axis for LEC specification. The 
nuclear receptor Coup­TFII (Lin et al., 2010; Srinivasan et al., 
2010) has an earlier developmental role as a venous identity factor, 
but it also directly interacts with Prox1 (Lee et al., 2009; Yamazaki 
et al., 2009) and regulates the expression of LEC­specific genes, 
such as neuropilin­2 (Nrp2; Lin et al., 2010).
Prox1/LYVE­1–positive cells bud and migrate dorsolater­
ally from the central veins. They subsequently form the first bona 
fide lymphatic structures (jugular lymph sacs) in regions where 
lymphangiogenic growth factor Vegf­c is provided by the lateral 
mesoderm (Fig. 2 A; Karkkainen et al., 2003). This process occurs 
at several positions along the anterior–posterior axis of the 
early embryo and results in the formation of jugular, medial, and 
axial lymph sacs, which further give rise to a primary capillary 
plexus (Sabin, 1902). Vegf­c is critical in the process: Vegfc/ 
mice lack all lymphatic vasculature, and even Vegfc+/ displays 
lymphatic hypoplasia (Karkkainen et al., 2003). The sprouting 
response of LECs to VEGF­C is mediated by the receptor tyro­
sine kinase VEGFR­3 and its nonsignaling transmembrane co­
receptor Nrp2 (Fig. 2 C). Nrp2 is highly expressed in lymphatic 
capillaries and becomes internalized together with VEGFR­3 
upon stimulation of LECs with VEGF­C and VEGF­D (Kärpänen 
et al., 2006a). Intriguingly, Nrp2 is important for capillary sprout­
ing but dispensable for the formation of lymph sacs (Yuan et al., 
2002; Xu et al., 2010). Vegfr­3 is initially expressed also in BECs 
but becomes mostly restricted to LECs after E10.5. Vegfr­3 sig­
naling depends on interaction with claudinlike protein Clp24 and 
receptor internalization, a process requiring ephrin­B2 (Saharinen 
et al., 2010; Wang et al., 2010). Interestingly, the combined dele­
tion of Vegfr­3 ligands Vegfc and Vegfd in mice does not pheno­
copy the inactivation of Vegfr3, pointing to a ligand­independent 
Vegfr­3 function (Haiko et al., 2008). Budding of LECs from 
veins requires Vegfr­3 kinase activity, whereas deletion of the 
Vegfr3 ligand­binding domain does not alter lymph sac formation 
(Fig. 2, A–C; Zhang et al., 2010). Proteolytically processed 
VEGF­C also interacts with VEGFR­2, which is expressed by 
lymphatic endothelium. However, activation of Vegfr­2 alone 
promotes lymphatic vessel enlargement but not sprouting 
(Wirzenius et al., 2007). VEGF­C induces formation of VEGFR­2/
VEGFR­3 heterodimers at angiogenic tip cells, suggesting that 
heterodimerization of VEGFR­3 with VEGFR­2 may contribute 
to lymphangiogenic sprouting (Nilsson et al., 2010). Endothelial­
specific loss of Rho GTPase Rac1 leads to an abnormally close 
association of lymph sacs and cardinal veins, suggesting that it 
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stabilization, and they also control lymphatic vascular develop­
ment. Mice hypomorphic for Tie1 exhibit LEC hyperplasia and 
abnormal remodeling of lymph sacs, whereas mice deficient in 
one of the Tie2 ligands, angiopoietin­2, show defective lymphatic 
vascular remodeling and lack valves (Gale et al., 2002; Dellinger 
et al., 2008; D’Amico et al., 2010). Tie2 activation induces 
phosphoinositide (PI) 3­kinase and Akt signaling in vitro, and 
consistent with these observations, mutations in several PI3­kinase 
pathway components or loss of Akt1 leads to lymphatic­remodeling 
defects (Gupta et al., 2007; Mouta­Bellum et al., 2009; Zhou 
et al., 2010). Zebrafish tie2/ undergoes normal lymphangio­
genesis. However, redundancy with Tie1 needs to be examined 
(Gjini et al., 2011).
Pathological lymphatic vascular 
morphogenesis
Given the importance of lymphatic vessels for normal body 
functions, it is not surprising that defects of the lymphatic vascu­
lature are implicated in a variety of human pathologies. Roles of 
lymphatic vessels in tumor metastasis and inflammation have 
been recently covered in several excellent reviews (Sleeman 
et al., 2009; Tammela and Alitalo, 2010). Here, we will concen­
trate on the defects of vascular morphogenesis in human lymph­
edema syndromes and some rare but debilitating diseases in 
which lymphatic vasculature is suggested to play a central role.
Hereditary lymphedema syndromes. Lymphatic 
vessel dysfunction results in progressive accumulation of protein­
rich interstitial fluid and formation of nonpitting localized tis­
sue swelling or lymphedema (Fig. 3). It is a chronic debilitating 
condition associated with increased local susceptibility to infec­
tions and certain cancers, such as angiosarcoma. Lymphedema 
can be inherited (primary lymphedema) but is more com­
monly caused by damage incurred by collecting lymphatic 
vessels or lymph nodes during cancer surgery or radiation ther­
apy (secondary lymphedema). Pathologies of secondary lymph­
edema have recently been reviewed (Rockson, 2001, 2008; 
Tammela and Alitalo, 2010).
Hereditary lymphedema is a rare genetic disorder, which 
can develop in utero, neonatally, or more frequently, years or de­
cades after birth (Fig. 3 and Table II). Missense mutations within 
the VEGFR­3 tyrosine kinase domain cause Milroy disease, which 
is characterized by underdeveloped and dysfunctioning cutaneous 
lymphatic vessels (Karkkainen et al., 2000; Mellor et al., 2010). 
Recently, mutations in the recessive CCBE1 gene, shown to con­
trol lymphatic sprouting in zebrafish (Hogan et al., 2009a), have 
been identified in a subset of Hennekam syndrome patients, who 
develop limb lymphedema, dilated intestinal lymphatic vessels, 
mental retardation, and facial anomalies (Alders et al., 2009). 
Intestinal lymphatic capillaries are also reduced in number and 
abnormally patterned, suggesting that defective lymphatic capil­
lary function is a cause of the syndrome (Alders et al., 2009).
Loss­of­function mutations in FOXC2 cause lymphedema–
distichiasis syndrome (LD), which is characterized by late onset 
lymphedema and a double row of eyelashes (distichiasis; Fang 
et al., 2000). Gain­of­function mutations in FOXC2 occur in 
patients with lymphedema, but the association of these muta­
tions with distichiasis awaits further investigation (van Steensel 
cascades mediated by spleen tyrosine kinase (Syk), Slp76, and 
PLC­2, which then lead to formation of the blood clot that seals 
off the vein from the lymph sac (Ichise et al., 2009; Bertozzi 
et al., 2010; Suzuki­Inoue et al., 2010).
In addition to platelets, myeloid cells regulate lymphatic vas­
cular morphogenesis. Macrophage­deficient PU.1/ and Csfr1/ 
mice exhibit hyperplastic dermal lymphatic capillaries, suggesting 
that macrophages restrict proliferation of LECs (Gordon et al., 
2010). Conversely, abnormal accumulation of myeloid cells, pro­
ducing high levels of cytokines and VEGF­D, induces the forma­
tion of dermal lymphaticovenous shunts in Syk/ mice (Böhmer 
et al., 2010). Similar mechanisms are likely at play in Angptl4/ 
mice, in which excessive macrophage activation by chylomicrons 
may be responsible for fusion of intestinal blood and lymphatic 
vessels (Bäckhed et al., 2007; Lichtenstein et al., 2010).
Lymphatic vascular remodeling and maturation. 
Starting from E15.5, the lymphatic vasculature is reorganized into 
lymphatic capillaries, precollectors, and collecting lymphatic ves­
sels (Fig. 2 A). In mice, transient up­regulation of the forkhead 
transcription factor Foxc2 is the first sign of formation of collecting 
lymphatic vessels (Norrmén et al., 2009). Lymphatic valves con­
tinue to express high levels of Foxc2 and Prox1 throughout devel­
opment and in adults. LECs in any given lymphangion decrease the 
expression of Prox1, Vegfr­3, LYVE­1, and Ccl21, secrete base­
ment membrane components, and acquire SMC coverage (Mäkinen 
et al., 2005; Norrmén et al., 2009). In the absence of Foxc2, transi­
tion from capillary to collecting lymphatic vessel phenotype and 
formation of lymphatic valves are arrested (Petrova et al., 2004; 
Norrmén et al., 2009). FOXC2­bound enhancers in LECs are sur­
rounded by nuclear factor of activated T cells (NFAT) binding 
sites, and pharmacological inhibition of NFAT activation results in 
lymphatic patterning defects reminiscent of Foxc2/ phenotypes 
(Norrmén et al., 2009). This suggests that Foxc2 and NFAT path­
ways cooperate in establishing collecting lymphatic vessels.
Ephrin–Eph signaling is essential for embryonic angio­
genesis, and targeted inactivation in mice of ephrin­B2 or its re­
ceptor EphB4 leads to aberrant embryonic blood vessel formation 
(Adams and Eichmann, 2010). Reverse signaling via PDZ inter­
action sites of ephrin­B2 is also required for the maturation of 
collecting lymphatic vessels (Mäkinen et al., 2005). In mice, the 
presence of a mutation in this PDZ interaction site of ephrin­B2 
prevents the formation of valves and leads to persistent LYVE­1 
expression in presumptive collecting vessels. These mutant mice 
also display defective sprouting of lymphatic capillaries, which 
acquire ectopic SMC coverage (Mäkinen et al., 2005).
Integrin 9 and its ligand fibronectin (FN) containing the 
EIIIA domain (FN­EIIIA) control later steps of lymphatic valve 
formation (Bazigou et al., 2009). The integrin 9–1 complex 
binds to FN­EIIIA, tenascin, and osteopontin in vitro and regu­
lates the organization of FN­EIIIA microfibrils. Loss of integrin 9 
prevents the elongation of valve leaflets, resulting in the forma­
tion of ringlike constrictions, which are unable to prevent lymph 
backflow (Bazigou et al., 2009). Fn-EIIIA/ mice have a similar 
phenotype, demonstrating that FN­EIIIA is a physiologically 
relevant integrin 9 ligand (Bazigou et al., 2009).
The Tie1 and Tie2 endothelial receptor tyrosine kinases 
are essential for blood vascular remodeling, maturation, and 
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distant sites, where they may block lymphatic function, causing 
accumulation of lymph in the chest and abdominal cavity and 
lymphedema. The cystic destruction of the lung parenchyma 
over time impairs lung function, which is ultimately only rescu­
able through lung transplantation (Seyama et al., 2010).
The kinase mammalian target of rapamycin (mTOR) plays 
a central role in integrating growth factor–activated signaling. 
Its abnormal activation is a likely cause of LAM, as patients 
with germline mutations of mTOR repressors tuberosis sclero­
sis complex­1 and ­2 (TSC1 and TSC2) genes develop the dis­
ease. Somatic biallelic loss of TSC2 occurs in sporadic LAM 
cases (Carsillo et al., 2000; Sato et al., 2002). In line with these 
findings, encouraging results were observed in patients treated 
with mTOR inhibitors (Glasgow et al., 2010). Given the close 
association of LAM cells with lymphatic vessels and the lym­
phatic pattern of dissemination, combining the blockage of 
mTOR with antilymphangiogenic therapy seems to be a reason­
able further step in developing better treatment for this disease.
Gorham disease (GD). GD is a rare disease of unknown 
etiology characterized by bone resorption and local vascular pro­
liferation. The disease is frequently complicated by systemic 
dysfunction of lymphatic vessels, such as chylothorax and chy­
lous ascites (Radhakrishnan and Rockson, 2008). Endothelial 
cells in the lesions are likely of LEC origin, as they express LEC 
markers LYVE­1 and podoplanin, and VEGFR­3 is increased 
in 50% of vessels (Hagendoorn et al., 2006). Nonendothelial 
cells from GD lesions resemble immature osteoclasts; they se­
crete cytokines and angiogenic factors, are highly invasive, and 
may, thus, contribute to disease progression (Colucci et al., 
2006). Moreover, GD osteoclast precursors show increased sen­
sitivity to humoral factors, promoting osteoclast formation and 
bone resorption (Hirayama et al., 2001). Overall, the clinical pic­
ture points to an intriguing link between LEC proliferation and 
activation of osteoclast­mediated bone resorption; however, at 
present, no candidate genes for GD have been identified.
Kaposi sarcoma (KS): a case of mixed identity. 
KS is a tumor caused by human herpes virus 8 (HHV8 or 
et al., 2009). Lymphatic vessel density is normal or increased in 
LD patients; however, lymphatic transport is inefficient because 
of lymph reflux, likely caused by incompetent lymphatic valves. 
LD patients also have venous reflux, suggesting a common 
mechanism for the morphogenesis of venous and lymphatic 
valves (Brice et al., 2002; Mellor et al., 2007)
Dominant­negative mutations in SOX18 occur in hypo­
trichosis–lymphedema–telangiectasia syndrome (HLT) character­
ized by sparse hair, swelling of legs, and dilation of small blood 
vessels. Based on phenotypic similarities with mice producing a 
dominant­negative form of Sox18, HLT patients likely have lym­
phatic capillary hypoplasia (Irrthum et al., 2003; François et al., 
2008). Novel causes of hereditary lymphedema include muta­
tions in gap junction protein GJC2 and protein tyrosine phospha­
tase PTPN14 (Au et al., 2010; Ferrell et al., 2010). GJC2 is highly 
expressed by oligodendrocytes, and recessive loss­of­function 
mutations in GJC2 cause hereditary Pelizaeus–Merzbacher­like 
disease, which is characterized by central nervous system de­
myelination. Given the dominant character of GJC2 mutations in 
lymphedema, mutant proteins might exert a dominant­negative 
effect either on remaining wild­type GJC2 molecules or other 
connexins. A subset of Ptpn14­deficient mice has hyperplas­
tic lymphatic vasculature, and a role for PTPN14 in restricting 
Vegfr­3 activation has been proposed (Au et al., 2010).
Lymphangioleiomyomatosis (LAM). LAM is a rare 
lung disease affecting women of childbearing age characterized 
by the proliferation of smooth muscle–like cells and lymphatic 
vessels as well as the formation of pulmonary cysts. LAM can 
also occur in the axial lymphatics and is associated with a benign 
kidney tumor angiomyolipoma (Seyama et al., 2010). The origin 
of the SMCs in LAM lesions is unknown, but they respond to 
estrogen and express multiple chemokine receptors and lym­
phangiogenic growth factors VEGF­C and VEGF­D, which may 
explain the highly metastatic behavior of LAM cells and their 
close association with lymphatic vessels (Pacheco­Rodriguez 
et al., 2009; Yu et al., 2009). LAM is a benign neoplasm. However, 
LAM cells frequently disseminate through lymphatic vessels to 
Figure 3. Causes of human hereditary lymph-
edemas. Lymph transport can be impaired 
because of a hypoplastic initial lymphatic capil-
lary network, because of abnormal coverage of 
lymphatic capillaries with basement membrane 
components and SMCs or because of a lack 
of or malfunctioning lymphatic valves. Defec-
tive lymphatic drainage leads to tissue fibrosis 
and fat deposition caused by the abnormal 
local chronic inflammatory response. Genes that 
are mutated in human hereditary lymphedema 
are indicated in blue next to the processes to 
which they are thought to be causally related. 
Mechanisms of the action of GJC2, PTPN14, 
and IKBKG are not fully understood.
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production of proangiogenic and inflammatory cytokines, and un­
restricted replicative potential (Mesri et al., 2010). Notably, some 
of these molecules control endothelial cell differentiation in vitro: 
four KS micro­RNAs target the transcription factor MAF and con­
tribute to reprogramming of the LEC to BEC phenotype, whereas 
kaposin­B stabilizes PROX1 mRNA, which has a key role in 
lymphatic endothelial identity (Hansen et al., 2010; Yoo et al., 
2010). Overall, these data provide an intriguing example of virus­ 
mediated change of the endothelial cell differentiation program.
Open questions and outlook
Impressive progress has been achieved in the past decade in the 
field of lymphatic vascular biology, but many questions remain 
KS­associated herpes virus [KSHV]). The lesions are composed 
of spindle­shaped tumor cells, leaky and highly proliferative 
vessels, extravasated red blood cells, and inflammatory infiltrate 
(Mesri et al., 2010). KS cells express markers of both blood 
(CD34 and CXCR4) and LEC lineages (VEGFR­3, LYVE­1, and 
podoplanin). Interestingly, KSHV infection of BECs shifts the 
transcriptional profile toward a LEC phenotype, whereas KSHV 
infection of LECs induces transcriptional reprogramming toward 
a more BEC­like phenotype (Hong et al., 2004; Wang et al., 2004).
The major latency viral transcripts expressed in KS cells 
include the latency­associated nuclear antigen, viral cyclin, vFLIP, 
viral­encoded micro­RNAs, and kaposin­A and ­B. These 
transcripts are important for KHSV­induced cell proliferation, 
Table II. Main human hereditary lymphedema syndromes
Name Inheritance MIM number Main manifestations Mutated gene Candidate locus
Syndromes with lymphedema as a primary manifestation
Hereditary lymphedema IA 
(Milroy disease)
Autosomal dominant  
with reduced  
penetrance
153100 Congenital lymphedema, chylous  
ascites caused by hypoplasia of  
lymphatic vessels
FLT4 (VEGFR-3) 5q35.3
Hereditary lymphedema IB Autosomal dominant  
with reduced  
penetrance
611944 Lymphedema of lower limbs, nature  
of lymphatic vascular defects is  
unknown
Unknown 6q16.2–q22.1
Hereditary lymphedema IC Autosomal dominant 613480 Lymphedema of limbs, age of onset 
1–15 yr, nature of lymphatic  
vascular defects is unknown
GJC2 (connexin47) 1q41–q42
Hereditary lymphedema II  
(Meige disease)
Unknown 153200 Puberty onset lymphedema, nature  
of lymphatic vascular defects is  
unknown
Unknown Unknown
Syndromes with lymphedema as a consistent feature
Anhidrotic ectodermal dysplasia 
with immunodeficiency,  
osteopetrosis and lymphedema
X-linked recessive 300301 Severe infections, osteopetrosis,  
nature of lymphatic vascular  
defects is unknown
IKBKG (Nemo) 
TER420TRP
Xq28
Cholestasis-lymphedema  
syndrome (Aagenaes syndrome)
Autosomal recessive 214900 Severe neonatal cholestasis, neonatal  
or childhood onset lymphedema 
caused by hypoplasia of lymphatic 
vessels
Unknown 15q1
Hennekam lymphangiectasia-
lymphedema syndrome
Autosomal recessive 235510 Lymphedema of limbs, intestinal  
lymphangiectasia, mental  
retardation, facial anomalies
CCBE1 18q21.32
HLT syndrome Autosomal dominant 607823 Alopecia, ectatic blood vessels,  
lymphedema, nature of lymphatic 
vascular defects is unknown
SOX18 20q13.33
Lymphedema, microcephaly,  
chorioretinopathy syndrome
Autosomal dominant 152950 Congenital microcephaly and  
lymphedema, nature of lymphatic 
vascular defects is unknown
Unknown Unknown
Lymphedema-choanal atresia 
syndrome
Autosomal recessive 608911 Blockage of nasal passage (choana), 
lymphedema of lower legs at  
4–5 yr, nature of lymphatic  
vascular defects is unknown
PTPN14 1q32–q41
Lymphedema–distichiasis syn-
drome, yellow nail syndrome
Autosomal dominant 153400/ 
153300
Late onset leg lymphedema and  
metaplasia of Meibomian glands 
(distichiasis), impaired lymphatic 
drainage caused by incompetent 
lymphatic valves
FOXC2 6q24.3
Persistence of mullerian deriva-
tives with lymphangiectasia and 
postaxial polydactyly (Urioste 
syndrome)
Autosomal recessive? 235255 Intestinal and pulmonary  
lymphangiectasia, protein-losing  
entheropathy, polydactyly, and  
mullerian duct remnants
Unknown Unknown
Pulmonary congenital lymphan-
giectasia
Unknown 265300 Congenital pulmonary lymphangiecta-
sia, subcutaneous edema,  
nonimmune hydrops, chylothorax
Unknown Unknown
References can be found under the corresponding Online Mendelian Inheritance of Man (MIM) entry.
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unresolved. Development of novel imaging techniques and 
analysis of signaling pathways in situ will certainly provide ad­
ditional insights into the mechanisms of lymphangiogenesis. 
Considerable phenotypic plasticity of endothelial cells is now 
obvious; however, the genetic and epigenetic mechanisms of 
LEC differentiation are far from being fully understood. Contri­
butions of other cell types in regulating lymphatic development 
and function need to be addressed under physiological and 
pathological conditions. Finally, organ­ and disease­specific 
features and responses of lymphatic endothelium have not been 
studied in detail, although this knowledge may have a critical 
impact on developing better treatments for human pathologies, 
including lymphedema, cancer, and inflammation.
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